NCT03102320 2022-06-30
ARCS-Multi
Bayer
Phase 1 Completed
Clinical Trials
6 trialsNCT02696642 2021-07-09
Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment
Bayer
Phase 1 Completed
NCT02610140 2020-11-04
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Bayer
Phase 2 Completed
NCT02824042 2020-07-31
Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole
Bayer
Phase 1 Completed
NCT02751918 2019-11-22
Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Bayer
Phase 1 Completed
NCT02639091 2019-11-07
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
Bayer
Phase 1 Completed